BioSpace News Archive

Aptinyx Inc. announced the closing of its public offering of 16,100,000 shares of its common stock, which included the exercise in full of the underwriters’ option to purchase additional shares, at a public offering price of $3.00 per share.

Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq: EGRX) today announced that the Company will release its 2020 third quarter financial results on Monday, November 2, 2020, before the market opens. Scott Tarriff, Chief Executive Officer, and Pete Meyers, Chief Financial Officer, will host a conference call to discuss the results as follows: Date Monday, November 2, 2020

– Promising findings featuring XL092, Exelixis’ next-generation oral tyrosine kinase inhibitor, recently presented at the 32 nd EORTC-NCI-AACR (ENA) Symposium –

Sunovion Pharmaceuticals Inc. announced that the company is marking ten years since it was established in October 2010.

VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced the presentation of two abstracts featuring data from the Phase 3 program evaluating Sci-B-Vac ® , the company’s 3-antigen prophylactic hepatitis B (HBV) vaccine, in e-poster present

Accenture (NYSE: ACN) and the Massachusetts Institute of Technology (MIT) are co-developing a supply chain resilience stress test for assessing operational and financial risks created by major market disruptions, disasters or other catastrophic events.

CANbridge Pharmaceuticals Inc., a company developing and commercializing innovative drugs to treat rare diseases and targeted cancers, announced that it has appointed Yunxiang Zhu, PhD, to the position of VP/Head of Global Research, overseeing all research and development and responsible for all drug development programs, from early discovery to the pre-clinical stage

Tribe Public announced that Dietrich Stephan, Ph.D., Chief Executive Officer of NeuBase Therapeutics, Inc., a biotechnology company accelerating the genetic revolution using a new class of synthetic medicines, will present at Tribe Public’s Presentation and Q&A Webinar Event at 8:30 a.m. PDT / 11:30 a.m. EDT on Wednesday, October 28th, 2020.

Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, and EVERSANA™, a leading provider of global commercial services to the life science industry, are pleased to announce the commercial launch of Gimoti™ (metoclopramide) nasal spray for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis.

In conjunction with Diabetes Awareness Month in November, the American Association of Clinical Endocrinology announced the launch of the ‘The Lowdown on Low Blood Sugar’ campaign to raise awareness of hypoglycemia, also known as low blood sugar, and help people at risk be prepared for a low blood sugar emergency.